AbbVie Partnership Program(s)
Not Disclosed
Pre-clinicalActive
Key Facts
About EvolveImmune Therapeutics
EvolveImmune Therapeutics is a private, clinical-stage biotech founded in 2019 and based in Branford, Connecticut. The company is developing a pipeline of trispecific T-cell engagers designed with built-in CD2 costimulation via its EVOLVE platform, targeting improved efficacy in solid tumors. Its lead program, EVOLVE104, has entered Phase 1 trials in 2025, and the company has secured a notable partnership with AbbVie. EvolveImmune is positioned in the competitive but high-potential field of next-generation T-cell engagers for oncology.
View full company profileTherapeutic Areas
Other Not Disclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| SAGE-689 | Sage Therapeutics | Phase 1 |
| SAGE-904 | Sage Therapeutics | Preclinical |
| BO-212 | Highlight Therapeutics | Research |
| Newzen-138 | Newzen Pharma | Not Disclosed |
| Immunozen | Newzen Pharma | Not Disclosed |
| Newzen-40 | Newzen Pharma | Not Disclosed |
| FYB209 | Formycon | Preclinical/Technical Development |
| FYB210 | Formycon | Preclinical/Technical Development |
| Undisclosed Target | Libra Therapeutics | Discovery |
| Eli Lilly Collaboration Program(s) | PepLib Biotech | Discovery/Pre-clinical |
| AstraZeneca Collaboration Program(s) | PepLib Biotech | Discovery/Pre-clinical |
| SRSD101 | Sirius Therapeutics | Phase 1 |